BFLY vs NNOX vs VREX Stock Comparison

Butterfly Network, Nano-X Imaging and Varex Imaging Prices as of Oct 27, 2026 Peers: Industry group
BFLY Butterfly Network, Inc.
$7.40 -21.2% 1M +236.4% 1Y
Market cap
$2.05B
P/E
–
Revenue (TTM)
$112.15M
Div. yield
–
Diagnostic Equipment Healthcare
3 wins
NNOX Nano-X Imaging Ltd.
$0.32 -50.0% 1M -92.1% 1Y
Market cap
$20.99M
P/E
–
Revenue (TTM)
$15.63M
Div. yield
–
Diagnostic Equipment Healthcare
2 wins
VREX Varex Imaging Corp
$18.46 +0.1% 1M +54.9% 1Y
Market cap
$776.75M
P/E
35.1x
Revenue (TTM)
$865.00M
Div. yield
–
Diagnostic Equipment Healthcare
4 wins

Head to Head

9 decided of 12

Varex Imaging leads on 4 of the 12 questions below (Varex Imaging 4, Butterfly Network 3, Nano-X Imaging 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBFLYNNOXVREXLeader
Larger companyMarket capitalisation $2.05B $20.99M $776.75M BFLY
Cheaper on earningsLower P/E, profitable companies only -27.3x -0.2x 35.1x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — — 21.2x –
Faster revenue growthRevenue growth, trailing twelve months +28.1% +31.5% +5.3% NNOX
More profitableNet margin, trailing twelve months -66.7% -747.2% 2.6% VREX
Better return on capitalReturn on invested capital — -116.9% 6.9% VREX
Less leveragedLower net debt / EBITDA — 0.3x 2.5x NNOX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +236.4% -92.1% +54.9% BFLY
Better 5-year returnAnnualised price return, 5 years -6.3%/yr -57.4%/yr -7.3%/yr BFLY
Less volatileAnnualised volatility, 1 year 114.8% 105.8% 57.5% VREX
Higher overall scoreMean of the five percentile scores vs peers 45/100 36/100 51/100 VREX

Percentile Scorecard

BFLYNNOXVREX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBFLYNNOXVREX
Valuation 28 #164 of 227 54 #105 of 227 87 #31 of 227
Growth 68 #71 of 219 10 #198 of 219 23 #168 of 219
Profitability 32 #140 of 206 10 #185 of 206 66 #70 of 206
Financial Health 61 #94 of 238 71 #71 of 238 42 #139 of 238
Shareholder Returns 37 #85 of 134 – 35 #88 of 134
Overall 45 36 51
  • BFLY ranked among 247 companies in Medical Devices and Diagnostics
  • NNOX ranked among 247 companies in Medical Devices and Diagnostics
  • VREX ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBFLYNNOXVREXSPY
1 month -21.2%-50.0%+0.1% -0.2%
3 months +3.1%-63.6%+65.9% +3.9%
6 months +43.4%-82.2%+52.9% +8.2%
Year to date +94.7%-88.6%+58.5% +12.9%
1 year +236.4%-92.1%+54.9% +12.3%
3 years +836.7%-93.6%+6.7% +87.4%
3 years, per year +110.9%-60.1%+2.2% +23.3%
5 years -27.6%-98.6%-31.4% +67.9%
5 years, per year -6.3%-57.4%-7.3% +10.9%

Risk

MeasureBFLYNNOXVREXSPY
Volatility, 1Y 114.8%105.8%57.5% 12.7%
Downside volatility, 1Y 91.7%116.3%50.0% 12.7%
Beta vs S&P 500, 1Y 3.001.361.11 1.00
Return / volatility, 1Y 2.06-0.870.95 0.97
Max drawdown, 5Y -93.4%-98.8%-78.8% -25.4%
From 52-week high -25.6%-93.0%-0.6% -1.2%
52-week high $9.94$4.55$18.58 $779.14
52-week low $1.97$0.32$9.32 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBFLYNNOXVREX
P/E now vs peer median -25.9xmedian 29.6x -0.2xmedian 29.6x 35.2xmedian 29.6x
P/S now vs peer median 15.7xmedian 2.9x 1.4xmedian 2.9x 0.9xmedian 2.9x
EV/EBITDA now vs peer median -22.6xmedian 17.4x 0.1xmedian 17.4x 10.2xmedian 17.4x
P/FCF now vs peer median -62.8xmedian 22.3x -0.4xmedian 22.3x -38.5xmedian 22.3x
P/B now vs peer median 9.3xmedian 2.3x 0.3xmedian 2.3x 1.5xmedian 2.3x
PEG now vs peer median -0.96median 1.04 -0.08median 1.04 -9.17median 1.04

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBFLYNNOXVREX
Revenue $112.15M $15.63M $865.00M
Gross profit $59.04M -$52.76M $296.90M
Operating income -$79.38M -$119.69M $72.20M
Net income -$74.85M -$116.81M $22.40M
Free cash flow -$28.04M -$52.09M -$20.20M
R&D $38.10M $18.93M $91.40M
EPS (diluted) $-0.29 $-1.80 $0.52
Cash & equivalents $124.66M $31.02M $99.20M
Total debt – $12.50M $347.10M
Shares (diluted) 262.10M 64.79M 42.60M
Enterprise value $1.49B -$158.68M $308.55M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBFLYNNOXVREX
P/E -25.9x -0.2x 35.2x
P/FCF -62.8x -0.4x -38.5x
P/Operating cash flow -73.3x -0.5x 68.9x
P/S 15.7x 1.4x 0.9x
P/B 9.3x 0.3x 1.5x
P/Tangible book 9.6x 0.4x 1.6x
EV/EBITDA -22.6x 0.1x 10.2x
EV/EBIT -20.6x 0.0x 14.2x
EV/Revenue 14.6x -0.4x 1.2x
EV/FCF -58.4x 0.1x -50.8x
EV/Operating cash flow -68.1x 0.1x 90.8x
PEG (3Y EPS CAGR) -0.96 -0.08 -9.17

Growth

14 metrics
MetricBFLYNNOXVREX
Revenue growth (1Y) 28.1% 31.5% 5.3%
Revenue CAGR (3Y) 15.6% 17.7% -1.2%
Gross profit growth (1Y) 8.8% -340.0% 6.1%
Gross profit CAGR (3Y) 13.3% -101.8% 1.2%
Operating income growth (1Y) -14.8% -107.4% 297.8%
Operating income CAGR (3Y) 21.1% -5.0% -2.3%
Net income growth (1Y) -19.1% -109.9% 116.7%
Net income CAGR (3Y) 20.8% -4.9% -9.2%
EPS growth (1Y) -12.9% -90.0% 116.1%
EPS CAGR (3Y) 27.0% 2.3% -3.8%
Operating cash flow growth (1Y) 19.6% -21.9% -81.1%
Operating cash flow CAGR (3Y) 44.5% -2.7% -47.6%
Free cash flow growth (1Y) 12.2% -19.4% -155.5%
Free cash flow CAGR (3Y) 42.8% 1.3% -33.5%

Profitability

14 metrics
MetricBFLYNNOXVREX
Gross margin 52.6% -337.5% 34.3%
EBITDA margin -64.4% -692.4% 11.7%
Operating margin -70.8% -765.6% 8.3%
Pretax margin -66.7% -758.5% 3.2%
Net margin -66.7% -747.2% 2.6%
FCF margin -25.0% -333.2% -2.3%
Operating cash flow margin -21.4% -298.7% 1.3%
Return on equity -39.3% -117.5% 4.5%
Return on assets -26.3% -98.6% 2.1%
Return on invested capital – -116.9% 6.9%
Return on capital employed -35.1% -114.2% 8.0%
Asset turnover 0.4x 0.1x 0.8x
Cash conversion (OCF / net income) 0.3x 0.4x 0.5x
Stock comp / revenue 21.3% 34.9% 1.7%

Financial Health

11 metrics
MetricBFLYNNOXVREX
Debt / assets – 3.3% 31.6%
Debt / equity – 0.0x 0.7x
Net debt / EBITDA – 0.3x 2.5x
Debt / FCF – -0.1x -17.2x
Liabilities / assets 33.1% 20.5% 53.6%
Equity / assets 66.9% 79.5% 46.4%
Interest coverage -59.4x – 1.9x
Current ratio 4.1x 2.8x 3.4x
Quick ratio 2.7x 2.4x 1.3x
Cash ratio 2.1x 2.3x 0.5x
Altman Z-score 7.05 -11.07 2.29

Shareholder Returns

7 metrics
MetricBFLYNNOXVREX
Dividend yield – – –
Net buyback yield -0.4% – -0.4%
Shareholder yield -0.4% – -0.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBFLYNNOXVREX
Forward P/E – – 21.2xFY2026
EPS, next fiscal year $-0.10FY2026 $-1.31FY2026 $0.87FY2026
EPS growth, next FY – – -3.3%FY2026
EPS growth, the year after – – +14.9%
Revenue, next fiscal year $114.50MFY2026 $18.64MFY2026 $829.68MFY2026
Revenue growth, next FY +17.3%FY2026 +43.2%FY2026 -1.8%FY2026
Revenue growth, the year after +26.0% +59.6% +2.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBFLYNNOXVREX
Held by institutions 59.9% 14.9% 95.2%
Institutions holding 245 102 186
Change in shares held, QoQ +13.9% -46.0% -2.7%
Institutions buying 143 55 98
Institutions selling 59 28 58
Buyers to sellers 2.42 1.96 1.69

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BFLYNNOXVREX
BFLY 1.00 0.16 0.19
NNOX 0.16 1.00 0.14
VREX 0.19 0.14 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BFLY, NNOX and VREX?

Butterfly Network (BFLY) is the largest by market capitalisation: Butterfly Network (BFLY) $2.05B, Nano-X Imaging (NNOX) $20.99M, Varex Imaging (VREX) $776.75M.

Which company is growing faster?

Nano-X Imaging (NNOX) grew revenue fastest over the trailing twelve months: Butterfly Network (BFLY) +28.1%, Nano-X Imaging (NNOX) +31.5%, Varex Imaging (VREX) +5.3%.

Which company is more profitable?

Varex Imaging (VREX) has the highest net margin (Butterfly Network (BFLY) -66.7%, Nano-X Imaging (NNOX) -747.2%, Varex Imaging (VREX) 2.6%). On return on invested capital, Varex Imaging (VREX) leads (Nano-X Imaging (NNOX) -116.9%, Varex Imaging (VREX) 6.9%).

Which stock has performed better?

Over the past year Butterfly Network (BFLY) returned the most: Butterfly Network (BFLY) +236.4%, Nano-X Imaging (NNOX) -92.1%, Varex Imaging (VREX) +54.9%. Over five years, Butterfly Network (BFLY) compounded fastest (Butterfly Network (BFLY) -6.3%/yr, Nano-X Imaging (NNOX) -57.4%/yr, Varex Imaging (VREX) -7.3%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Varex Imaging (VREX) has been the steadiest (Butterfly Network (BFLY) 114.8%, Nano-X Imaging (NNOX) 105.8%, Varex Imaging (VREX) 57.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BFLY, NNOX and VREX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Varex Imaging (VREX) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.